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It has been proposed that the N-linked glycan of the minor proteins of porcine reproductive and
respiratory syndrome virus (PRRSV) is important for the production of infectious virus. In this study, we
showed that N-linked glycosylation of GP2 is not essential for virus viability and none of the individual
glycosylation sites in GP3 has a vital effect on the production of infectious virus. Moreover, mutations of
single and double glycosylation sites in GP4 are not critically important for infectious virus recovery,
triple and quadruple mutations are lethal. The bimolecular ﬂuorescence complementation (BiFC)
analysis also showed that GP4, but might be not GP2, is involved in interaction with cellular receptor
CD163 and that glycosylation of GP4 might not play a vital role in the interaction with CD163. The
study further revealed that none of the N-glycosylation sites in the minor proteins is critical for the
susceptibility of mutants to neutralizing antibody.
& 2012 Elsevier Inc. All rights reserved.Introduction
The porcine reproductive and respiratory syndrome virus (PRRSV)
is the causative agent of porcine reproductive and respiratory and
syndrome in the swine population (Paton et al., 1991). The disease
was ﬁrst reported in Europe and in the USA in the early 1990s and it
has since become a problem to the swine industry worldwide
(Collins et al., 1992; Wensvoort et al., 1991). PRRSV belongs to the
order Nidovirales, family Arteriviridae, genus Arterivirus. Other related
viruses of the family Arteriviridae are equine arteritis virus (EAV),
lactate dehydrogenase-elevating virus (LDV) and simian hemorrhagic
fever virus (SHFV) (Plagemann and Moennig, 1992; Snijder and
Meulenberg, 1998). PRRSV is divided into two genotypes, the
European, or type I, virus and the American, or type II, virus. The
two genotypes show approximately 60% genome sequence homol-
ogy (Fang and Snijder, 2010; Forsberg, 2005).
PRRSV contains a positive-stranded RNA genome of approximately
15.4 kilobases and has nine open reading frames (ORFs). The ORF1a
and ORF1b encode viral replicase polyproteins that are translated
immediately upon viral entry, and processed proteolytically by virally
encoded proteinases into 13–14 nonstructural proteins (NSPs) (Fang
and Snijder, 2010). The NSPs are also responsible for replication ofll rights reserved.genomic RNA, transcription of subgenomic RNA, and some of them
could be antagonism of IFN and TNF-a (Beura et al., 2010; Chen et al.,
2010; Kim et al., 2010; Subramaniam et al., 2010). The ORFs 2–5
encode the glycosylated membrane proteins GP2–GP5, ORF6 encodes
a non-glycosylated membrane protein (M), and ORF7 encodes the
nucleocapsid (N) protein. The ORF2b is fully embedded in ORF2 and
encodes the small, non-glycosylated E protein. The recently discov-
ered ORF5a protein may be a novel small structural protein, of which
the coding gene overlaps partially the 50 end of ORF5 (Firth et al.,
2011; Johnson et al., 2011). All of these structural proteins except the
ORF5a protein are required for the generation of infectious virions
(Firth et al., 2011; Molenkamp et al., 2000; Wissink et al., 2005),
which indicates that they play critical roles in virion assembly and/or
interactions with the cell surface receptors to allow virus entry. The
major components of the PRRSV envelope are GP5 and M, which are
known to form disulﬁde-linked heterodimers and that formation of
such heterodimers is required for viral assembly and infectivity, and
also for binding to the cellular receptor pig sialoadhesin (pSn)
(Mardassi et al., 1996; Van Breedam et al., 2010). The interaction
between the M/GP5 glycoprotein complex and pSn is critically
dependent on the sialic acid-binding capacity of pSn, as well as on
the presence of sialic acids on GP5 (Van Breedam et al., 2010). The
minor envelope glycoproteins GP2a, GP3, GP4 and the unglycosylated
2b interact with each other to form a heterotetrameric complex in
infected cells and that formation of this complex is required for the
generation of infectious virions (Das et al., 2010; Mardassi et al., 1996;
Wissink et al., 2005). The GP4 and GP2a proteins also may serve as
Fig. 1. Schematic representation of the 30 end of the APRRS strain genome. Boxed
numbers represent the open reading frames of the structural proteins, including
the recently reported ORF5a. The positions of the consensus sequences for
N-linked glycosylation in the glycosylated proteins are indicated (%).
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molecule to allow virus entry into susceptible host cells (Das et al.,
2010).
N-linked glycosylation of minor proteins of PRRSV plays
diverse functions in virus infectivity, receptor binding and stimu-
lation of the immune response. The GP2 protein of North Amer-
ican type II PRRSV contains two predicted N-glycosylation sites, at
positions N178 and N184. It has been shown that both glycosyla-
tion sites are used for the addition of glycan (Das et al., 2011).
Previous studies based on the type II FL12 virus have shown that
glycan addition at position N184 is required for production of
infectious virus, and that glycosylation at position N178 has no
effect on growth of the mutant virus in MARC-145 cells. The study
also showed that glycosylation of at least one site in the GP2
protein is necessary for efﬁcient interaction with the receptor
CD163 (Das et al., 2011). In contrast, loss of the N173- or 179-
linked glycan, corresponding to the N178 and N184 site in type II
PRRSV, in a mutant of type I Lelystad virus does not prevent the
virus from displaying efﬁcient growth in MARC-145 cells, and
mutations at these two glycosylation sites does not affect virus
recovery (Wissink et al., 2004). The GP3 protein has seven
potential N-linked glycosylation sites, at positions N29, N42,
N50, N131, N152, N160, and N195. It has been shown that all
the glycosylation sites except N195 are used for glycosylation,
and that glycosylation at positions N42, N50, and N131 is critical
for the production of infectious virus (Das et al., 2011). The virus
named PRRSV-01 lacks two N-glycosylation sites naturally in its
envelope glycoproteins, one in GP3 at position N131 and the other
in GP5 at position N51, is sensitive to neutralizing antibody
(Vu et al., 2011). It is suggested that PRRSV performs immune
evasion through glycan shielding that involves both GP5 and GP3
(Ansari et al., 2006; Vu et al., 2011). The GP4 protein contains four
predicted N-glycosylation sites, at positions 37, 84, 120, and 130.
It has been shown that the four glycosylation sites are used for
glycan addition, and that mutation of single glycosylation sites in
GP4 does not affect infectious virus recovery but multiple muta-
tions are lethal. The glycosylation of GP2 and GP4 is believed to be
required for efﬁcient interaction with CD163 (Das et al., 2011).
Previous studies on glycosylation ablation in the minor pro-
teins of PRRSV did not address whether removal of the glycosyla-
tion per se or the associated structural changes in the proteins
accounted for the observed deleterious effects on the replication
of PRRSV. The latter scenario is supported by the existence of
natural PRRSV isolates devoid of N-glycosylation in the minor
proteins, which implies that the existence of some minor protein-
associated glycans is not vital to the virus life cycle. In this study,
we showed that the N-linked glycosylation of GP2 is not essential
for virus viability. None of the individual glycosylation sites in
GP3 has a vital effect on the recovery of infectious virus. More-
over, the mutations of single or double glycosylation sites in GP4
are not critically important for production of infectious virus but
triple or quadruple mutations are lethal. The BIFC results showed
that GP4 but might be not GP2 is involved in interactions with the
cellular receptor CD163, for which glycosylation of GP4 might not
play a vital role in interaction with CD163. The study further
revealed that removal of glycosylation site at N131 in GP3 does
not render the virus susceptible to convalescence serum.Results
N-linked glycosylation of GP2 is not essential for virus viability
The GP2 protein of North American type II APRRSV strain
contains two predicted N-glycosylation sites, at positions N178
and N184 (Fig. 1). It has been shown that both glycosylation sitesare used for glycan addition, and that addition of the glycan at
amino acid position N184 is critical for recovery of infectious
virus (Das et al., 2011). However, some strains of PRRSV have no
such speciﬁc N-linked glycosylation site at position N178 or N184
in GP2, including the strains EDRD-1 (GenBank accession No:
AB288356) and PrimePac PRRS vaccine (GenBank accession:
AF066384), in which no glycosylation site at positions 178 and
184, respectively, are found. This implies that the existence of
GP2-associated glycan is not vital to the virus life cycle. Based on
the full-length infectious cDNA clone pAPRRSasc (Tian et al.,
2011), full-length cDNA clone mutants were generated in which
codons for relevant Asn residues at positions 178 and 184 were
replaced by codons for Try and Asp, which were present in the
strains EDRD-1 and PrimePac PRRS vaccine, respectively. Three
recombinant full-length cDNA clones were constructed and
designated as pCGP2N178Y, pCGP2N184D, and pCGP2N178Y/
184D. The recombinant full-length cDNA clones, as well as the
parent plasmid pAPRRSasc, were transfected into BHK-21 cells. At
48 h post-transfection (h.p.t.), the supernatant of the transfected
cells was harvested to infect fresh MARC-145 cells. The infected
cells were analyzed by immunoﬂuorescence assay (IFA) using
antibody (D5-4) against the PRRSV N protein. All mutants
expressed PRRSV N protein and spreaded into the neighboring
cells at 48 h post-inoculation (h.p.i), as shown in Fig. 2a. These
results showed that infectious viruses were recovered readily
from the cells transfected with full-length CMV-launched DNA
clones containing mutations at N178, N184 or N178/184 in GP2.
Recombinant viruses carrying single or double glycosylation sites
mutation replicated and propagated well in MARC-145 cells,
which suggests that N-linked glycosylation of GP2 is not essential
for virus viability.
To determine the replication characteristics of wt and mutants
carrying single or double glycosylation sites mutation in the GP2
protein, we analyzed ﬁrst whether the mutant viral particles were
less infectious. To this end, we infected MARC-145 cells with
0.01 MOI of wt (vAPRRSasc) and mutant viruses (vCGP2N178Y,
vCGP2N184D, and vCGP2N178Y/184D), multi-step growth kinetics
were analyzed by titrating the supernatants of infected cells. The
supernatants were harvested at the indicated time points (12, 24,
48, 72, 96, and 120 h) from MARC-145 cells infected with wt and
mutants. The amount of infectious particles was determined by
assessment of the TCID50. The results revealed that the growth
kinetics of the recovered viruses carrying a single glycosylation site
mutation was similar to that of the wt virus, and the overall yield of
mutants did not show signiﬁcant differences when compared with
wt. However, the multiple-step growth curve of the mutant carry-
ing mutations at two glycosylation sites had different growth
behavior from the wt. As shown in Fig. 2b, the mutants reached
their peak titer at 96 h.p.i, about 24 h delayed with respect to wt.
The overall yield of mutants was nearly one log less than that of wt.
The viral plaque assay was performed on MARC-145 cells to
monitor the plaque phenotype of the mutant viruses. As shown in
Fig. 2c, the majority of the plaques generated by wt and the variants
containing a single glycosylation site mutation were clear and
distinct. However, plaques produced by mutants carrying double
glycosylation sites mutation were smaller than those produced by
Fig. 2. N-linked glycosylation of GP2 is not essential for infectious virus recovery. (a) PRRSV N protein expression identiﬁed by IFA. The mutant plasmids with mutations at
single or both glycosylation sites in GP2, along with the parental pARRSVasc full-length plasmids, were used to transfect BHK-21 cells. The transfectant supernatants were
harvested at 48 h.p.t., and inoculated into fresh MARC-145 cells. The infected MARC-145 cells were ﬁxed and stained at 24 h.p.i. using a monoclonal antibody (D5-4)
against the PRRSV N protein and anti-mouse secondary antibody labeled with Alex-four (Sigma). Images were taken at 200 magniﬁcation. (b) Multi-step growth kinetics
of wt and various mutants in MARC-145 cells. Cells in six-well plates were infected with PRRSV at an MOI of 0.01, culture supernatants were collected at the indicated time
points after infection, and virus titers were determined. Average titers with standard deviations (error bars) from three independent experiments are shown. (c) Viral
plaque morphology: Ten-fold serially diluted mutants were inoculated into fresh MARC-145 cells in six-well plates, cultured in EMEM containing 1% agarose overlay, ﬁxed
at 4 d.p.i., and stained with 1% crystal violet.
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in GP2 does not affect the recovery of infectious virus and removal
of the two glycans from GP2 affect virus growth and production of
infectious virus.
To conﬁrm that mutations introduced into the viral RNA were
maintained in the replicating viruses, the RNA of the serially
passaged viruses (P3) was puriﬁed from viral particles and used in
RT-PCR and nucleotide sequencing analysis of the ORF2 to 7. We
found that all of the engineered mutations in GP2 were retained
in the recombinant viruses, and no conspicious mutations in the
ﬂanking regions were found (data not shown).
None of the individual glycosylation sites in GP3 is essential for virus
viability
The GP3 protein has seven potential N-linked glycosylation sites,
at positions N29, N42, N50, N131, N152, N160, and N195. It has been
shown that all the glycosylation sites except N195 are used for
glycosylation, and glycosylation at positions N42, N50, and N131 was
reported to be critical for infectious virus production (Das et al.,
2011). However, previous investigation has not established whether
the growth-defective phenotype is attributable to the loss of glyco-
sylation per se, or to structural alteration to the GP3 protein that
results from the amino acid substitution. In addition, some PRRSV
ﬁeld strains, such as the strain PRRSV-01 (Genbank accession:
JF422072), bear Asn by Ser amino acid mutations at position N131,
which suggests that the glycan at N131, and other glycosylation sites
on GP3, may be not critically important for the virus life cycle. In this
study, the mutation Asn to Ser was selected in the seven potential
glycosylation sites, because this substitution was likely to introducefew modiﬁcations of the protein structure. To this end, we generated
recombinant clones with speciﬁc mutations in each of the potential
glycosylation sites in GP3. These glycosylation sites were removed by
changing the Asn to Ser in a cDNA clone of PRRSV. The wt and
mutated clones carrying the N29S, N42S, N50S, N131S, N152S, N160S,
and N195S substitutions (pCGP3N29S, pCGP3N42S, pCGP3N50S,
pCGP3N131S, pCGP3N152S, pCGP3N160S, and pCGP3N195S) were
used to transfect BHK-21 cells. At 48 h.p.t., the supernatant of the
transfected cells was harvested to infect fresh MARC-145 cells. Viral
replication in MARC-145 cells was analyzed by IFA using antibody
against the PRRSV N protein (D5-4). As Fig. 3a shows, most of the
monolayer cells were IFA positive at 48 h.p.i. This result indicated that
none of the individual glycosylation sites in GP3 is essential for virus
viability.
The results of multiple step growth curve analysis showed
that the growth kinetics of the recovered viruses that carried a
glycosylation site mutation at positions N29, N131, N152, N160,
and N195 (vCGP3N29S, vCGP3N131S, vCGP3N152S, vCGP3N160S,
and vCGP3N195S) were similar to that of the wt virus, and the
overall yield of mutant viruses did not show signiﬁcant differences
from wt (Fig. 3b). However, the overall yield of mutants carrying a
glycosylation site mutation at position N42 or N50 (vCGP3N42S,
vCGP3N50S) was nearly one log less than that of wt. The plaque
phenotype assay showed that the majority of the plaques pro-
duced by wt and the variants that contained a single glycosylation
site mutation at positions N29, N131, N152, N160, or N195 were
clear and distinct. However, the plaques produced by mutants
carrying N42 or N50mutation gave rise to smaller plaques than wt
and the other variants (Fig. 3c). These results indicate that the loss
of glycan at N42 or N50 somehow affects virus growth kinetics.
Fig. 3. Mutation of individual glycosylation sites in GP3 is not critically important for infectious virus recovery. (a) IFA of the MARC-145 cells infected with the transfectant
supernatants collected from the BHK-21 cells transfected with mutants with N-linked glycosylation site mutations in the GP3 protein. The IFA analysis was performed at
48 h.p.i. using monoclonal antibodies against the PRRSV N protein. Images were taken at 200 magniﬁcation. (b) Multi-step growth kinetics of wt and variants bearing the
individual glycosylation site mutations in the GP3 protein in MARC-145 cells. Cells in six-well plates were infected with PRRSVs at an MOI of 0.01, culture supernatants
were collected at the indicated time points after infection, and the virus titers were determined by TCID50. Average titers with standard deviations (error bars) from three
independent experiments are shown. (c) Viral plaque morphology: Ten-fold serially diluted mutants with individual glycosylation site mutations in GP3 were inoculated
into fresh MARC-145 cells in six-well plates, cultured in EMEM containing 1% agarose overlay, ﬁxed at 4 d.p.i., and stained with 1% crystal violet.
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maintained in the replicating viruses, the ORF2-3’UTR regions of
the mutant viruses carrying mutation in GP3 were ampliﬁed by
RT-PCR and sequenced. The result showed the existence of the
engineered deletions in all of the passaged viruses, and no other
mutations were detected in the ORF2-3’UTR coding region, which
suggests that the glycosylation site mutations in the GP3 protein
were indeed dispensable for virus viability (data not shown).
Mutation of single and double glycosylation sites in GP4 does not
have a vital effect on the recovery of infectious virus
The GP4 protein contains four predicted N-glycosylation sites, at
positions 37, 84, 120, and 130 (Fig. 1). It has been shown that the
four glycosylation sites are used for glycan addition, and that
mutation of single glycosylation sites in GP4 does not affect
infectious virus recovery but multiple mutations are lethal (Das
et al., 2011). In this study, to generate recombinant clones with
speciﬁc mutations in each of the potential N-glycosylation sites in
GP4, these glycosylation sites were destroyed by changing the Asn
to Ser in a cDNA clone of PRRSV. The wt and mutants carrying
the N37S, N84S, N120S, and N130S substitution (pCGP4N37S,
pCGP4N84S, pCGP4N120S, and pCGP4N130S) were transfected into
BHK-21cells. At 48 h.p.t., the supernatant of the transfected cells
was harvested to infect fresh MARC-145 cells. Viral replication in
MARC-145 cells was analyzed by IFA using antibody (D5-4) against
the PRRSV N protein at 48 h.p.t. As shown in Fig. 4a, most of the
monolayer cells were IFA positive. The result indicates that muta-
tion of single glycosylation site in GP4 does not affect the recovery
of infectious virus. In the analysis of multi-step growth kinetics and
the virus plaque assay, as shown in Fig. 4b and c, the growth
kinetics and virus plaques of the recovered variants (vCGP4N84S,
vCGP4N120S, and vCGP4N130S) carrying a single glycosylation site
mutation at N84, N120, or N130 showed no apparent difference
from those of the wt virus, which suggests that a single glycosyla-
tion site mutation at these positions in GP4 has no effect on growthof the mutant virus in MARC-145 cells. However, the overall yield of
the viral particles produced by the variant (vCGP4N37S) with the
glycosylation mutation at N37 was 5-fold less and the plaques were
smaller than those of wt, which suggests that this mutation affects
the production of infectious virus particles.
To generate mutations at two or more glycosylation sites in
GP4, the single glycosylation site constructs were used as tem-
plates, and clones carrying multiple glycosylation sites mutation
were generated. The double (pCGP4N37/84S, pCGP4N37/120S,
pCGP4N37/130S, and pCGP4N84/120S), triple (pCGP4N37/84/
120S, pCGP4N37/120/130S, pCGP4N37/84/130S, and pCGP4N84/
120/130S), and quadruple (pCGP4N37/84/120/130S) glycosylation
sites mutants were transfected into BHK-21 cells. At 48 h.p.t., the
supernatant of the BHK-21 cells was collected to infect MARC-145
cells. The IFA was performed on the infected MARC-145 cells using
an antibody against PRRSV N protein to analyze the replication of
the mutants. The result showed that all the double glycosylation
sites mutants, but not the triple and quadruple glycosylation sites
mutants, expressed the PRRSV N protein and had spread into
neighboring cells at 48 h.p.i., as shown in Fig. 4a. This suggests
that double glycosylation sites mutation in GP4 does not have a
vital effect on recovery of infectious virus, but triple and quad-
ruple glycosylation sites mutation in GP4 are lethal. Subsequently,
we analyzed the multiple-step growth curve and performed
the viral plaque assay on the mutant viruses (vCGP4N37/84S,
vCGP4N37/120S, vCGP4N37/130S, and vCGP4N84/120S). The mul-
tiple-step growth curve of the mutants carrying double glycosyla-
tion sites mutation had similar growth behavior to that of the wt.
However, the overall yield of the mutants was nearly one log less
than that of wt, as shown in Fig. 4c. Plaques produced by the
mutants carrying double glycosylation sites mutation were indis-
tinct and smaller than those of the wt, as shown in Fig. 4d. These
results indicate that double glycosylation sites mutation in GP4
are not critical for virus recovery but they affect the production of
infectious virus. To assess their genetic stability, the ORF2-3’UTR
regions of the mutant viruses were ampliﬁed by RT-PCR and
Fig. 4. Mutation of single and double glycosylation sites in GP4 does not have a vital effect on infectious virus recovery, but triple or more mutations are lethal. (a) IFA
analysis of MARC-145 cells at 24 h.p.i. with wt and mutants bearing single or double glycosylation sites mutation in GP4. The IFA analysis was performed at 24 h.p.i. using
a monoclonal antibody (D5-4) against PRRSV N protein. Images were taken at 200 magniﬁcation. (b) Multi-step growth kinetics of wt and variants bearing the single
mutation in the GP4 protein in MARC-145 cells. Cells in six-well plates were infected with PRRSVS at an MOI of 0.01, culture supernatants were collected at the indicated
time after infection, and virus titers were determined by TCID50. Average titers with standard deviations (error bars) from three independent experiments are shown.
(c) Multi-step growth kinetics of wt and variants bearing double glycosylation site mutations in the GP4 protein in MARC-145 cells. Average titers with standard deviations
(error bars) from three independent experiments are shown. (d) Viral plaque morphology. Ten-fold serially diluted mutants with individual glycosylation site mutations in
GP4 were inoculated into fresh MARC-145 cells in six-well plates, then cultured in EMEM containing 1% agarose overlay, ﬁxed at 4 d.p.i. and stained with 1% crystal violet.
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absence of any other unplanned mutations (data not shown).
GP4 but not GP2 might be involved in interaction with cellular
receptor CD163
The GP2 and GP4 proteins have been shown to interact
speciﬁcally with the CD163 molecule, which can function as a
receptor for PRRSV entry (Das et al., 2010). Furthermore, it has
been demonstrated by the Co-immunoprecipitation (Co-IP) assay
that the glycosylation of GP2 and GP4 is important for efﬁcient
interaction with CD163 (Das et al., 2011). However, in this study,
we showed that the glycosylation sites in GP2 are not critically
important for virus infectivity, which suggests that the glycans of
GP2 may not play a critical role in the interaction with CD163. To
conﬁrm the result of the Co-IP performed previously by Das et al.
(2011), we carried out BiFC (bimolecular ﬂuorescence comple-
mentation) analysis in BHK-21 cells. To obtain the BiFC construct,
the venus protein was spliced between amino acid residues 173
and 174, which resulted in the fragments VN (N-terminal 173
residues) and VC (C-terminal 66 residues). The ‘‘Target’’ protein
was fused to the N terminus of VN or VC with a linker sequence
to generate the BiFC pair, as shown in Fig. 5a. To assess the
speciﬁcity of the BiFC method, fragments VN and VC, or a-tubulin
gene-fused VN and GP2, GP3, and GP4 fused with VC, wereco-transfected into BHK-21 cells. As shown in Fig. 5b, no ﬂuorescent
signals were observed at 24 h.p.t., which suggest that BiFC can be
used to study the interaction between CD163 and the minor
proteins. Subsequently, BiFC was used to investigate the interaction
between CD163 and the minor proteins. The minor proteins GP2,
GP3, and GP4 were fused to the N-terminus of the VC fragment,
respectively, and CD163 was fused to the N-terminus of the VN
fragment. The BHK-21 cells were co-transfected with plasmids
encoding the fusion proteins CD163-VC and GP2-VN, GP3-VN, or
GP4-VN. The results showed that the speciﬁc BiFC signal was found
in cells co-transfected with GP4-VN and CD163-VN, which suggests
that GP4 co-localize with CD163. However, BHK-21 cells co-
transfected with CD163-VN and GP2-VC or GP3-VC showed no
BiFC signal under the same conditions, as shown in Fig. 5b. No
signiﬁcant BiFC ﬂuorescence was detectable in cells transfected
with CD163-VN, GP2-VC, GP3-VN, or GP4-VN alone (data not
shown). The BiFC analysis thus suggests that GP4, but might be
not GP2 or GP3, has a speciﬁc interaction with CD163 at the
cytoplasm circumference in BHK-21 cells.
To determine whether glycosylation of GP4 is involved in the
interaction with CD163, BiFC analysis was performed. Full-length
ORF4 cDNA carrying the single, double, triple, or quadruple
glycosylation sites mutation was ampliﬁed by PCR and inserted
into BiFC vectors as fusions with the VC fragments. BHK-21
cells were co-transfected with VC fused with GP4 carrying the
Fig. 5. Bimolecular ﬂuorescence complementation (BiFC) analysis of minor proteins involved in the interaction with CD163. (a) Schematic diagram of BiFC constructs.
Venus protein was spliced between amino acid residues 173 and 174, resulting in fragments VN (N-terminal 173 residues) and VC (C-terminal 66 residues). The ‘‘Target’’
protein was fused to the N-terminus of VN or VC with a linker sequence to generate the BiFC pair. (b) Fragments VN and VC or a-tubulin gene-fused VN and minor proteins
fused with VC were co-expressed in BHK-21 cells, and the ﬂuorescent signals were examined to assess the speciﬁcity of the BiFC method. Plasmids encoding the fusion
proteins CD163-VC and GP2-VN, GP3-VN, GP4-VN, or GP4-VN carrying glycosylation site mutations were co-transfected into BHK-21 cells for 24 h. The BiFC ﬂuorescence
was imaged at 24 h.p.i.
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signiﬁcant BiFC ﬂuorescence was detectable in cells co-trans-
fected with CD163-VN and VC fused with GP4 carrying glycosyla-
tion mutations, which suggests that the glycosylation of GP4 may
not play a vital role in the interaction with CD163.
Inﬂuence of hypoglycosylation of minor proteins on PRRSV’s ability to
be neutralized by convalescence serum
It has been shown that PRRSV performs immune evasion
through glycan shielding that involves both GP5 and GP3
(Ansari et al., 2006; Vu et al., 2011). N-glycan at position N131
in GP3 of a type II PRRSV isolate (PRRSV-01) is as important as
N-glycans in GP5 regarding its role in protection of the virus from
antibody neutralization. However, the engineered viruses carry-
ing glycosylation mutations in the minor proteins are not sensi-
tive to convalescent serum (Das et al., 2011). In this study, we
obtained mutant viruses lacking one or two glycosylation sites
in the minor proteins, which failed to be rescued in the previous
study. The ability of these mutants to be neutralized by con-
valescent antisera needed further investigation. To this end,
convalescent antisera collected from pigs infected with vARRSV
and vAJXM, respectively, were used in ﬂuorescent focus neutraliza-
tion (FFN) analysis. The viruses with single glycosylation site muta-
tion (vCGP2N184D, vCGP3N42S, vCGP3N50S, and vCGP3N130S) and
those with double glycosylation sites mutation (vCGP2N178Y/184D,vCGP2N37/84S, vCGP2N37/120S, vCGP2N37/30S, and vCGP2N84/
120S) were used as the challenge viruses in serum neutralization
assays. As shown in Table 2, the wt (vAPRRS), which lacks the
N-glycosylation sites in the hypervariable region upstream of the
neutralization epitope in GP5 naturally (GenBank accession:
GQ330474), was sensitive to the convalescent antisera collected from
pigs infected with vARRSV or vAJXM, high titers of homologous
(vAPRRSV-speciﬁc serum) and heterologous neutralizing antibodies
(vAJXM-speciﬁc serum) were detected in the sera collected at 49 d.p.i.
However, the differences observed among the mean titers of serum
from vARRSV- or vAJXM-infected pigs against the hypoglycosylated
PRRSV mutants and wt were not statistically signiﬁcant (p40.5),
which suggests that the removal of these glycans from the minor
proteins, including the N131-linked glycan from GP3, do not increase
the accessibility of the neutralizing epitope to convalescent antisera.
The removal of glycosylation site at N131 in GP3 does not render the
virus susceptible to antibody neutralization
It has been shown that the absence of N-glycosylation site at in
the hypervariable region upstream of the neutralization epitope in
the GP5 protein of engineered mutants and ﬁeld isolate increases the
susceptibility of the virus to antibody neutralization(Ansari et al.,
2006; Faaberg et al., 2006). In our study, the vAPRRSasc which lacks
the glycosylation site in the upstream of the N44 is also sensitive to
the antibody neutralization. To rule out the possibility that the
Fig. 6. Introduction of a glycosylation site at upstream of the neutralization
epitope in GP5 does not affect infectious virus recovery. (a) IFA of the MARC-145
cells infected with the transfectant supernatants collected from the BHK-21 cells
transfected with wt and mutants (vCGP5S34N and vCGP131SGP5S34N). The IFA
analysis was performed at 48 h.p.i. using monoclonal antibodies against the PRRSV
N protein. Images were taken at 200 magniﬁcation. (b) Multi-step growth
kinetics of wt and mutants (vCGP5S34N and vCGP131SGP5S34N) in MARC-145
cells. Cells in six-well plates were infected with PRRSVs at an MOI of 0.01, culture
supernatants were collected at the indicated time points after infection, and the
virus titers were determined by TCID50. Average titers with standard deviations
(error bars) from three independent experiments are shown.
Table 1
Susceptibility of different PRRSV mutants to convalescent serum.
Viruses Geometric mean endpoint in serum samples
vAPRRS vAJXM
vAPRRSasc 203.1 128
vCGP2N184D 203.1 101.5
vCGP2N178Y/184D 256 80.6
vCGP3N42S 256 80.6
vCGP3N50S 203.1 161.1
vCGP3N131S 256 101.5
vCGP4N37/84S 161.2 128
vCGP4N37/120S 203.1 101.5
vCGP4N37/130S 161.1 128
vCGP4N84/120S 203.1 101.5
vCGP5S34N 32 25.3
vCGP3N131SGP5S34N 25.3 25.3
Anti-serum was obtained at 49 day post-infection from pigs that had been
infected with vAPRRS or vAJXM. Neutralization titers were expressed as the
reciprocal of the highest dilution that showed 90% or greater reduction in
the number of ﬂuorescent foci presenting in the control wells. The differences in
the mean titers of serum from pigs infected with vARRSV or vAJXM against the
hypoglycosylated PRRSV mutants and wt (vAPRRS) were not statistically signiﬁ-
cant, respectively (p40.5).
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conferred by deglycosylation of GP5 of vAPRRSasc is likely to mask,
partially or completely, any effects of deglycosylation of the minor
proteins, the fully glycosylated GP5 clones were constructed. To this
end, using pAPRRSasc and pCGP3N131S as a backbone, respectively,
N-glycosylation site was introduced into the glycan-missing posi-
tions in GP5 by mutating S34 to N. The clones (pCGP5S34N,
pCGP3N131SGP5S34N) were constructed and transfected into
BHK-21 cells. At 48 h.p.t., the supernatant of the transfected cells
was harvested to infect fresh MARC-145 cells. Viral replication in
MARC-145 cells was analyzed by IFA. As Fig. 6a shows, most of the
monolayer cells were IFA positive at 48 h.p.i. This result indicated
that the introduction of a glycosylation site at N34 in GP5 does not
affect infectious virus recovery. The multiple step growth
curve analysis showed that the growth kinetics of the recovered
viruses that carried a fully glycosylated GP5 (vCGP5S34N,
vCGP3N131SGP5S34N) were similar to that of the wt virus, and
the overall yield of mutant viruses did not show signiﬁcant
differences from wt (Fig. 6b). The ORF2-3’UTR regions of the
mutant viruses were ampliﬁed by RT-PCR and sequenced to
conﬁrm the presence of desired mutations and the absence of
any other unplanned mutations (data not shown).
To analysis whether the introduction of N-glycosylation site
in GP5 affect the susceptibility of the viruses (vCGP5S34N,
vCGP3N131SGP5S34N) to antibody neutralization, the FFN were
performed. The results showed that the introduction of a glycan at
position at N34 in the GP5 deduce the two viruses sensitivity to the
antibody neutralization. Low titers (r1:32) of homologous and
heterologous neutralizing antibodies were detected in the sera
(Table 1). The mutant vCGP3N131SGP5S34N with deletion of N-gly-
cosylation site at N131 is not sensitive to the antibody neutralization
compared to mutant vCGP5S34N. This suggests that introduction of
N34S into the GP5 makes the viruses less sensitive to neutralization
by an antiserum and removal of glycosylation site at N131 in GP3
does not render the virus susceptible to antibody neutralization.Discussion
Previous studies based on the type II FL12 virus have shown that
the addition of glycan at position 184 in GP2 and glycosylation at
positions N40, N52, and N131 in GP3 are required for the production
of infectious virus. The mutation of individual glycosylation site in
GP4 does not affect recovery of infectious virus, but multiple
mutations are lethal. The glycosylation of the GP2 and GP4 proteins
is required for efﬁcient interaction with CD163 (Das et al., 2011).
Our results showed that the N-linked glycosylation of GP2 is not
essential for virus viability. Moreover, none of the single glycosyla-
tion sites on GP3 has vital effect on infectious virus recovery. The
mutation of single and double glycosylation sites in GP4 is not
critical for infectious virus production, but triple and more muta-
tions are lethal. The BiFC results also showed that GP4, but might be
not GP2, is involved in interaction with the cellular receptor CD163,
and that glycosylation of GP4 might not play a vital role in
interaction of the virus with CD163. The study further revealed that
glycosylation of the minor proteins, including the N-linked glycosy-
lation at position 131 in GP3, which has been showed previously to
have an effect on the susceptibility of the virus to neutralization
antibody, is not sensitive to convalescent serum. These results made
signiﬁcant contributions to better understand the virus replication
and virus neutralizing mechanisms.
Previous studies based on the type I FL12 virus have shown
that addition of glycan at position N184 is required for the
production of infectious virus in MARC145 cells (Das et al.,
2011). Our present study shows clearly that this is not the case.
We found that loss-of-N178 or N184-linked glycan variants of
PRRSV can display efﬁcient growth in MARC-145 cells, and that
mutations at two glycosylation sites do not have a vital effect on
virus recovery in MARC-145 cells. The data we obtained are
consistent with those of the type I Lelystad virus (Wissink et al.,
2004). Therefore, these results indicate that the removal of the
glycans in GP2, per se, is not critical for the recovery of infectious
virus. We assume that the structural changes in the GP2 protein
caused by the amino acid substitution introduced to abolish
glycosylation accounted for the observed growth defective phe-
notypes. In our studies, variants with replacement of Asn184 by
Asp, a smaller hydrophilic amino acid residue, retained efﬁcient
growth. We also observed that the growth kinetics and the plaque
phenotype of the virus carrying the N184 glycosylation site
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N179 with Gln, a larger hydrophilic amino acid residue, did not
affect the infectivity of the type I Lelystad virus signiﬁcantly in
PAM (Wissink et al., 2004). However, replacement of N184 with
Ala, a small hydrophobic residue, was detrimental to infectious
virus recovery in the FL-12 virus in MARC-145 cells (Das et al.,
2011). In summary, it is suggested that the structural changes in
the GP2 protein introduced by the amino acid substitution that
destroys glycosylation, but not the glycan itself at position N184,
may account for the observed growth-defective phenotypes. In
contrast, the replacement of N178 with Ala in FL12 virus, or with
Tyr, a hydrophilic aromatic amino acid, and replacement of N173
in type I Lelystad virus with Gln, a larger hydrophilic amino acid
residue, did not affect the infectivity of the virus. This suggests that
the glycosylation at position N178 and the nature of the amino acid
residues (polar or nonpolar) introduced at this site are not critical
to infectious virus production. The observation of the N-glycosyla-
tion of GP2 of type I and type II PRRSV is not critically important for
virus infectivity in MARC-145 or PAM challenge the previous result
that glycosylation of at least one site in GP2 protein is necessary for
efﬁcient interaction with the receptor CD163 (Das et al., 2011).
Furthermore, our result showed that the GP2 might be not
involved in interaction with CD163 by performing BIFC in present
study. It is also contrast with the ﬁnding of previous study (Das
et al., 2010). Nevertheless, it is clear that more biochemical
information is required to clarify the exact role of the glycosylation
of GP2 claimed to be involved in interaction with CD163.
We also found that the glycosylation sites at N40, N52, and
N130 in GP3 are not critically important for recovery of infectious
virus. This is in contrast with a previous study, which showed that
the introduction of an Ala residue at positions N40, N52, and N130
in GP3 is lethal for infectious virus production (Das et al., 2011).
The discrepancy in the effect of the N-glycosylation sites at N40,
N52, and N130 on the growth of PRRSV may be due to differences
in the way in which the N-glycosylation sites are abolished. In our
study, the mutation of Asn to Ser, a hydrophilic residue that has
a similar conformation to Asn, was selected in these potential
glycosylation sites. This substitution is likely to introduce few
modiﬁcations to the protein structure. In addition, some ﬁeld
strains of PRRSV, such as the strain PRRSV-01 (Genbank accession:
JF422072), bear the Asn to Ser amino acid mutation at position
N131, which suggests that this glycan is not critically important in
the life cycle of the virus (Vu et al., 2011). This notion is also
supported by the observation that the mutant bearing a glycosyla-
tion mutation at N131 did not show altered virus infectivity in our
study. The growth kinetics and the plaque phenotype of the
mutant carrying the N131 glycosylation site mutation were similar
to those of the wt. We also observed that the glycosylation
mutation at N40 or N52 was not critically important for recovery
of infectious virus. However, the overall yield of the mutants was
nearly one log lower, and the plaques were smaller than those of
the wt. These results indicate that loss of glycan at residues 42 or
50 affect virus growth and infectious virus production.
We observed that a single glycosylation site mutation in GP4 is
not critical for recovery of infectious particles. The growth kinetics
and virus plaques of the recovered variants that carried single
glycosylation mutations at N84, N120, and N130 showed no
apparent difference from those of the wt virus. However, the
glycosylation mutation at N37 affected virus growth. This observa-
tion on the growth characteristics of the variants is different from
that of FL12 virus, in which single glycosylation mutation in GP4
resulted in variants with improved replication characteristics (Das
et al., 2011). It is possible that the replacement of Asn with Ala in
GP4 produces a better conformational structure for virus replica-
tion than replacement with Ser. The observation that mutation of
double glycosylation sites in GP4 does not have a vital effect on therecovery of infectious PRRSV is intriguing. It has been shown
previously that mutation of double glycosylation sites in FL12
virus prevented infectious virus recovery, despite the fact that
single glycosylation site mutation in GP4 give rise to mutants with
better growth characteristics (Das et al., 2011). Thus, it appears
that the nature of the amino acid substitutions introduced to
abolish multiple N-linked glycosylation sites may account for
differences in the requirement for glycosylation of GP4 in the
production of infectious virus. We also observed that the overall
yield of mutants carrying two glycosylation site mutations in GP4
was nearly one log lower and the plaques were indistinct and
smaller than those of wt. Most important of all, we also found that
triple or quadruple glycosylation mutations in GP4 were lethal,
which suggests that the presence of two glycosylation sites on GP4
is essential for virus viability. It is well known that N-linked
glycosylation is important for the correct folding, targeting, and
biological activity of proteins (Braakman and van Anken, 2000;
Chackerian et al., 1997; Doms et al., 1993; Shi and Elliott, 2004;
Wei et al., 2003). That improper folding of the mutant protein
caused by the ablation of N-linked glycans affects virus infectivity
has been reported for many enveloped viruses (Hanna et al., 2005;
Kim et al., 2008; Lee et al., 2010). In this study, the deletion of three
or more glycosylation sites in GP4 may cause improper folding of
the mutant protein, which affects the recovery of infectious virus.
BiFC is a newly emerged technique that is used to study
protein–protein interactions. It is a powerful tool to detect
in vivo weak or otherwise transient protein–protein interactions
with high levels of speciﬁcity and sensitivity (Hu and Kerppola,
2003; Kerppola, 2006; Shyu and Hu, 2008). In this study, BiFC was
performed to increase understanding of the interaction of CD163
and the minor proteins of PRRSV. The observation that GP4 but not
GP2 might have a speciﬁc interaction with CD163 in BHK-21 cells
is surprising. It contrasts with the data obtained by Co-IP that GP2
is involved in an interaction with CD163 (Das et al., 2011). Our data
also showed that the GP4 protein interacts with CD163. However,
the addition of glycan to GP4 might not play a critical role in the
efﬁcient interaction with CD163. In BHK-21 cells co-transfected
with CD-163-VC and wt, and with mutant GP4-VN, the interaction
between CD163 and GP4 was found to be independent of the
extent of glycosylation of GP4. A similar intensity of BiFC ﬂuores-
cence was shown in the co-transfected BHK-21 cells, which
suggests that the mutant that carries a glycosylation site mutation
interacts with CD163 as successfully as the wt GP4. Like other
assay systems, BIFC analysis has its limitations. The role of GP2 and
GP4 and their glycosylation in the interaction with CD163 requires
further conﬁrmation by different methods.
Our study showed that the wt (vAPRRSasc) that lacks the
N-glycosylation site in the hypervariable region upstream of the
neutralization epitope in GP5 naturally was sensitive to conva-
lescent antisera collected from pigs infected with vARRSV or
vAJXM. This is consistent with previous data showing that the
FL virus and natural isolate that carry a glycosylation site muta-
tion at N34 in GP5 is sensitive to convalescent antisera (Ansari
et al., 2006; Faaberg et al., 2006). Our study also showed that the
variants with mutations at two glycosylation sites in GP2 or GP4,
as well as other single glycosylation site mutations in the minor
proteins, are not more sensitive to the convalescent serum than
wt. It is suggested that the glycosylation of minor proteins does
not have an inﬂuence on the response of viruses to antibody
neutralization. This corroborates the previous ﬁnding that mutant
PRRSVs bearing hypoglycosylated forms of minor proteins are not
sensitive to convalescent serum (Das et al., 2011). We also concerned
that the increase in susceptibility to neutralization by antibody
conferred by deglycosylation of GP5 of vAPRRSasc is likely to interfere
with any effects of deglycosylation of the minor proteins. To solve this
issue, two mutants with fully glycosylated GP5 were constructed.
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neutralization by an antiserum that vAPRRSVasc. It is consistent with
previously studies showing that N-glycan addition at this site in GP5
help the virus escape neutralization by the host antibodies through
‘‘glycan shielding’’ (Ansari et al., 2006; Faaberg et al., 2006). We also
observed that the mutant vCGP3N131SGP5S34N with fully glycosy-
lated GP5 but carrying N-glycosylation site mutation at N131 in GP5
is not more sensitive to convalescent serum than vCGP5S34N. This
suggests that the removal of glycosylation site at N131 in GP3 does
not render the virus susceptible to antibody neutralization. It con-
trasts with the previous ﬁnding that the N-glycan at N131 in GP3 of a
type II PRRSV isolate (PRRSV-01) plays an important role in protection
of the virus from antibody neutralization (Vu et al., 2011). The
discrepancy between the two studies might be due to other amino
acid substitutions in the envelope proteins of PRRSV-01, rather than
the glycosylation site in GP3 at position N131, which affect the
sensitivity of the mutant to antibody neutralization.Materials and methods
Cells and antibodies
MARC-145 (ATCC, Manassas, VA) and baby hamster kidney cells
(BHK-21; ATCC CCL10) were maintained at 37 1C in EMEM (Gibco)
plus 10% fetal bovine serum (FBS) and DMEM (Gibco) supplementedTable 2
Primers used in this study.
Name Sequence (50–30)
GP2N178YF GCGCATGACGGGGTCATATGTAACCATAGTA
GP2N178YR ATATACTATGGTTACATATGACCCCGTCATGC
GP2N184DF ATGTAACCATAGTATATGATGGTACTTTGAA
GP2N184DR CTGATTCAAAGTACCATCATATACTATGGTTA
GP3N29SF GGTTGCGGGTCCCAGTGCTACGTAC
GP3N29SR GTACGTAGCACTGGGACCCGCAACC
GP3N40SF CTGGTTAGGGGCAGTTTTTCCTTCG
GP3N40SF CGAAGGAAAAACTGCCCCTAACCAG
GP3N52SF AGCTCTTGGTGAGTTACACGGTGTG
GP3N52SR CACACCGTGTAACTCACCAAGAGCT
GP3N131SF TTCGGGATAGGGAGTGTGAGCAAAG
GP3N131SF CTTTGCTCACACTCCCTATCCCGAA
GP3N152SF CATGATGGGCAGAGCACCACCTTGC
GP3N152SR GCAAGGTGGTGCTCTGCCCATCATG
GP3N160SF CCCCGCCATGACAGCTTTTCAGCCG
GP3N160SR CGGCTGAAAAGCTGTCATGGCGGGG
GP3N195SF TTGGTTGGTTTTAAGTGTCTCGTGG
GP3N195SR CCACGAGACACTTAAAACCAACCAA
GP4N37SR ACATTAAGACCAGCACCACCGCAGCA
GP4N37SF TGCTGCGGTGGTGCTGGTCTTAATGT
GP4N84SF CATTACAGCCAGCGTGACAGATGAGA
GP4N84SR CTCATCTGTCACGCTGGCTGTAATG
GP4N120SF GTGGTATTTGGCTCTGTGTCAGGCAT
GP4N120SR ATGCCTGACACAGAGCCAAATACCAC
GP4N130SF GCTGTGTGTGTTTCTTTTACCAGCT
GP4N130SR AGCTGGTAAAAGAAACACACACAGC
CD163SFEcoRI AAGAATTCATGGACAAACTCAGAATGGTGCT
CD163SRXhoI AACTCGAGTTGTACTTCAGAGTGGTCTCCTGA
SF12165 TTTAGGCCTGAATTGAGGCGCGCCAATG
SR14780 GCATCTAGAGGTGATGAACCTCCAAGTTTCT
GP2SFBglII GGAAGATCTATGAAATGGGGTCCATGC
GP2SRXhoI CCGCTCGAGCCAAGAGCTCGAAGGAAAAATT
GP3SFEcoRI CGGAATTCATGGCTGATAGCTGTGCAT
GP3SRXhoI CCGCTCGAGTCGCCGTGCGGCACTGAG
GP4SFEcoRI CGGAATTCATGGCTGCGTCCCTTCT
GP4SRXhoI CCGCTCGAGAACTGCCAACAGAATGG
SF12004 GTTTGAATCGGATACAGCGTA
QNT GAGTGACGAGGAGCGGCCGCTTTTTTTTTTT
GP5S34NF CAACGCCAGCTCCAACAGCAGCTCTC
GP5S34NR GAGAGCTGCTGTTGGAGCTGGCGTTG
Primer names are organized in groups. Preﬁxes: SF, forward PCR prim
indicated in italic letters.with 10% FBS, respectively. Monoclonal antibody (D5-4) against the
N protein of type I PRRSV was provided generously by Dr. Shaoying
Chen (Fujian Academy of Agricultural Sciences, China).
Plasmids
The PRRSV infectious cDNA clone pAPRRSasc, which contains
an Asc I restriction enzyme recognition site immediately
upstream of the ORF2 start codon (Tian et al., 2011), is a
derivative of the infectious clone pAPRRS (Yuan and Wei, 2008).
The intermediate vector, named pCBC23456, which contains the
sequences covering the ORF2–6 region was constructed from the
infectious clone pAPRRSasc. Glycosylation site mutations were
introduced at the glycosylation sites of the minor proteins in the
intermediate vector pCBC23456 using standard site-directed PCR
mutagenesis. The primers used in PCR mutagenesis are listed in
Table 2. After restriction enzyme map identiﬁcation and sequence
analysis, the fragments that harbored the desired mutations were
excised with Asc I and Xba I, and transferred subsequently into
the full-length clone pAPRRSasc to generate mutant plasmids.
DNA transfection and recovery of mutant viruses
Mutant plasmids were prepared using a QIAprep Spin Mini-
prep kit (Qiagen, Hilden, Germany), followed by identiﬁcation byApplication
TAT PCR mutagenesis for N178 of GP2
GC
TCAG PCR mutagenesis for N184 of GP2
CAT
PCR mutagenesis for N29 of GP3
PCR mutagenesis for N40 of GP3
PCR mutagenesis for N52 of GP3
PCR mutagenesis for N131 of GP3
PCR mutagenesis for N152 of GP3
PCR mutagenesis for N160 of GP3
PCR mutagenesis for N195 of GP3
PCR mutagenesis for N37 of GP4
PCR mutagenesis for N84 of GP4
PCR mutagenesis for N120 of GP4
PCR mutagenesis for N130 of GP4
ACATGAAAACTCT PCR ampliﬁcation for CD163
GGGATT
PCR construction for pCBC23456
ATGG
PCR ampliﬁcation of GP2–GP4 to
GC fuse to the BiFC
RT-PCR ampliﬁcation for ORF2–7
T
PCR mutagenesis for S34 of GP5
er; SR, reverse PCR primer. The restriction endonuclease sites are
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tiﬁcation by spectrophotometry. BHK-21 cells were grown to 70%
conﬂuence on six-well plates and the DNAs were transfected with
3.75 mg of each plasmid, using 18.75 ml Lipofectamine
TM
LTX and
3.75 ml Plus Reagent (Invitrogen) according to the manufacturer’s
instructions. Rescued mutant viruses were harvested on BHK-21
cell monolayers which were remarked as primary passage (P0),
and were used to infected MARC-145 cells for three passages
(P1 to P3) by 102 dilution at each passage.
Indirect immunoﬂuorescence assay
An indirect immunoﬂuorescence assay (IFA) was performed
for the detection of protein expression in cells infected with the
corresponding virus. Conﬂuent monolayers of MARC-145 cells
were infected with the mutant viruses. After 48 or 24 h post-
inoculation, the infected cells were washed twice with phos-
phate-buffered saline (PBS), followed by ﬁxation in cold metha-
nol, and blocked in 1% BSA at room temperature. The cells were
incubated with antibody against the PRRSV N protein at 37 1C for
2 h. After extensive washing with PBS, the cells were incubated
with anti-mouse Alexa-568-labeled secondary antibody (Sigma)
for 1 h. The cells were washed ﬁve times with PBS. Finally, the
ﬂuorescence was visualized under an Olympus inverted ﬂuores-
cence microscope equipped with a camera.
Multi-step growth curves
Subconﬂuent MARC-145 cells in a six-well plate were infected
with equal amounts of wt and the mutated viruses. A multiplicity
of infection (MOI) of 0.01 was used in each case as indicated.
After 1 h incubation at 37 1C, the cells were washed three
times with PBS and incubated into 3 ml of EMEM containing 2%
FBS in a CO2 incubator at 37 1C. At several time points
post-infection (12, 24, 48, 72, 96, and 120 h), cell supernatants
(0.2 ml/well) were collected and frozen at 70 1C. For virus
quantiﬁcation at each time point, a viral titer was measured in
MARC-145 cells by standard TCID50 assay using the method of
Reed and Muench.
Viral plaque assay
To examine the plaque morphology of the glycosylation
mutant viruses, 10-fold serially diluted virus suspensions were
incubated with MARC-145 cells in six-well plates. After adsorp-
tion for 1 h, the cell monolayers were washed off, and then
overlaid with a mixture of EMEM medium containing 2% FBS
and 1% low melting agarose (Cam-brex, Rockland, ME, USA).
When the agarose overlay had solidiﬁed, the plate was inverted
(bottom up) in a humidiﬁed CO2 incubator at 37 1C for 4 days. The
resulting plaques were stained with crystal violet (5% w/v1 in
20% ethanol).
RT-PCR and nucleotide sequence
Viral RNA was isolated from P1–P3 using a QiaAmp Viral RNA
kit (QIAGEN, Hilden, Germany) according to the manufacturer’s
instruction. Aliquots of 1 mg of RNAs were used to synthesize
ﬁrst-strand cDNA using Reverse Transcriptase XL (AMV) (TaKaRa
Dalian, China) and the anti-sense primer QNT. The fragment
containing the ORF2-ORF7 region was ampliﬁed using PfuUltra
II Fusion HS DNA Polymerase (Stratagene) with the forward
primer SF12004 and reverse primer QNT under the following
conditions: denaturation at 95 1C for 3 min, 30 cycles of denatura-
tion at 95 1C for 30 s, annealing at 58 1C for 30 s, and extension at
72 1C for 3 min, followed by a ﬁnal extension at 72 1C for 10 min.The PCR product was puriﬁed using a TIANgel Mini Puriﬁcation
Kit (TianGen) and sequencing.
Serum neutralization assays
The titer of PRRSV-neutralizing antibodies in each serum
sample was determined as described previously (Ansari et al.,
2006). Twofold dilutions of convalescent antisera, which were
heat-inactivated for 30 min at 56 1C prior to the neutralization
assay, were each mixed with an equal volume of culture medium
containing 200 TCID50 of test PRRSV mutants and wt. The mixture
was incubated at 37 1C for 1 h and added to MARC-145 cells in 96-
well tissue culture plates at a density of 1.2105 cells/well. After
incubation for 36 h at 37 1C in a humidiﬁed atmosphere contain-
ing 5% CO2, the cells were ﬁxed in cold methanol, and blocked in
1% BSA at room temperature. The cells were incubated with
antibody against the PRRSV N protein (D5-4) at 37 1C for 2 h.
After extensive washing with PBS, the cells were incubated
with anti-mouse Alexa-568-labeled secondary antibody (Sigma)
for 1 h. Subsequently, the cells were washed ﬁve times with
PBS. Finally, the ﬂuorescence was visualized under an Olympus
inverted ﬂuorescence microscope equipped with a camera.
Neutralization titers were expressed as the reciprocal of the
highest dilution that inhibited 90% of the foci present in the
control wells.
Bimolecular ﬂuorescence complementation analysis
The BiFC plasmids were constructed as described previously
(Nagai et al., 2002). Brieﬂy, the sequences encoding ﬂuorescent
protein Venus residues 1–173 (VN) or residues 174 to 239 (VC)
were connected by a C-terminus linker (GGGGS)3. Porcine CD163
cDNA was ampliﬁed using PCR from the total RNA isolated from
PAM cells using speciﬁc primers (Table 2) and fused to the
N-terminus of VN via a (GGGGS)3 linker. The coding regions of
GP2, GP3 and GP4 carrying glycosylation site mutations were
ampliﬁed and fused to the N-terminus of VC via a (GGGGS)3 linker.
The alpha-tubulin gene from the MARC-145 cell line was ampli-
ﬁed and fused to the N-terminus of VN to produce the negative
control. BHK-21 cells in six-well plates with about 70% conﬂuence
were co-transfected with 500 ng of each BiFC plasmid using the
Lipofectamine
TM
LTX and Plus Reagent (Invitrogen). At 24 h.p.i.,
live cells were visualized using an Olympus inverted ﬂuorescence
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